Hereditary Spastic Paraplegia 44 (SPG44): Comprehensive Disease Characterization Report

Disease: Hereditary Spastic Paraplegia 44 (SPG44) MONDO ID: MONDO:0013179 | OMIM (phenotype): 613206 | Category: Mendelian (autosomal recessive) Causal gene: GJC2 (= GJA12), connexin-47 (Cx47)

Summary

Hereditary Spastic Paraplegia 44 (SPG44) is an ultra-rare, autosomal recessive complicated hereditary spastic paraplegia caused by biallelic mutations in GJC2 (also known as GJA12), the gene encoding the oligodendrocyte gap-junction protein connexin-47 (Cx47). SPG44 occupies the mild end of a GJC2 allelic severity continuum whose severe pole is Pelizaeus–Merzbacher-like disease type 1 (PMLD1), also called hypomyelinating leukodystrophy 2 (HLD2, OMIM 608804). A third, mechanistically unrelated allelic disorder — autosomal dominant hereditary lymphedema type IC (LCRP1, OMIM 613480) — arises from other GJC2 variants affecting lymphatic endothelium. The landmark description of SPG44 (Orthmann-Murphy et al., 2009) reported three patients from one family homozygous for the GJC2 variant c.99C>G (p.Ile33Met, "I33M") who had late-onset, slowly progressive complicated spastic paraplegia with normal or near-normal psychomotor development, preserved walking through adulthood, no nystagmus, and MRI evidence of hypomyelinating leukoencephalopathy.

Mechanistically, SPG44 results from loss of functional Cx47 gap-junction channels, which disrupts oligodendrocyte–oligodendrocyte and oligodendrocyte–astrocyte ("panglial syncytium") coupling required to maintain CNS myelin. A key distinction from severe PMLD1 emerged from in-vitro work: severe PMLD1 mutants are retained in the endoplasmic reticulum (ER) and trigger the unfolded protein response (UPR) and apoptosis (a toxic gain-of-function component), whereas the mild SPG44 allele p.I33M shows wild-type-like subcellular distribution and a clean loss-of-function without ER stress or apoptosis. This mechanistic difference plausibly explains SPG44's comparatively benign, ambulation-preserving course.

There is no disease-modifying therapy for SPG44; management is symptomatic (baclofen, botulinum toxin, physiotherapy, orthotics). Proof-of-concept oligodendrocyte-targeted AAV-GJC2 gene therapy rescued pathology in Cx32/Cx47 double-knockout mice, and transgenic re-expression of connexins rescued the same model, validating a cell-autonomous, correctable loss-of-function mechanism. Prevention is limited to genetic counseling, carrier testing, and reproductive options (prenatal / preimplantation genetic testing) for known familial variants. Prognosis is favorable relative to PMLD1: the disorder is chronic, slowly progressive, and lifelong, but not typically fatal.

1. Disease Information

Overview. SPG44 is a form of complicated (syndromic) hereditary spastic paraplegia in which slowly progressive lower-limb spasticity is accompanied by a diffuse hypomyelinating leukoencephalopathy visible on brain MRI, together with variable cerebellar signs and, in a minority, mild peripheral neuropathy — while cognition and vision are largely spared. It is genetically defined by biallelic GJC2 mutations and is the mildest of the recognized GJC2-related CNS disorders.

Key identifiers.

Synonyms / alternative names. SPG44; spastic paraplegia type 44, autosomal recessive; GJC2/GJA12-related complicated hereditary spastic paraplegia. The gene is historically named GJA12 and currently GJC2.

Data provenance. Information is derived overwhelmingly from aggregated disease-level resources and small published case reports/family studies (the original Italian family and a subsequent Iranian family), plus mechanistic in-vitro and mouse-model literature — not from large EHR/individual-patient datasets, reflecting the disorder's extreme rarity.

2. Etiology

Causal factors. SPG44 is a monogenic, autosomal recessive genetic disorder caused by biallelic (homozygous or compound heterozygous) pathogenic variants in GJC2/GJA12 encoding connexin-47. There is no environmental, infectious, or acquired cause. The disease is fully explained by loss of Cx47 gap-junction function in oligodendrocytes. As stated in the landmark report, three patients from one family carried "a novel recessively inherited mutation, 99C>G (predicted to cause an Ile>Met amino acid substitution; I33M) that causes a milder phenotype" (PMID: 19056803).

Genetic risk factors. The sole risk determinant is the presence of two pathogenic GJC2 alleles. The originally described SPG44 allele is c.99C>G (p.Ile33Met, I33M) in the N-terminus; a novel homozygous variant c.G14T (p.Ser5Ile) was later reported in an Iranian family initially diagnosed as HSP (Ghasemi et al., 2023, PMID: 37915394). No modifier genes for SPG44 have been established.

Environmental risk / protective factors. None known or expected for a fully penetrant recessive Mendelian disorder. Consanguinity is an important epidemiologic enabler because it increases homozygosity for rare recessive alleles; reported families are frequently consanguineous (e.g., Iranian and Turkish GJC2 cohorts). No protective variants, dietary, or lifestyle factors have been identified.

Gene–environment interactions. No validated gene–environment interactions are described for SPG44.

3. Phenotypes

The core SPG44 phenotype (Orthmann-Murphy et al., 2009; p.I33M family) is late-onset, slowly progressive complicated spastic paraplegia with normal or near-normal psychomotor development, preserved independent walking into adulthood, and absence of nystagmus — distinguishing it from the allelic PMLD1. The original report states: "All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus" (PMID: 19056803).

Notably spared: early nystagmus, significant cognitive impairment, and severe early psychomotor delay — features that characterize the more severe allelic PMLD1. Brainstem auditory evoked potentials (BAEP) are typically recordable in GJC2 disease (contrast with absent BAEP waves III–V in PLP1-related PMD). In a comparative neurophysiology series, "NCS were normal in all patients with PMD and indicated mild peripheral neuropathy in only 2 of 10 patients with PMLD" (PMID: 20513814).

Quality-of-life impact. Progressive lower-limb spasticity impairs gait, mobility, and daily functioning over decades; however, preserved ambulation and cognition mean the QoL impact is substantially milder than in PMLD1. No SPG44-specific EQ-5D/SF-36 data exist; per-phenotype QoL metrics are extrapolated from the complicated-HSP literature.

4. Genetic / Molecular Information

Causal gene. GJC2 (= GJA12), located on chromosome 1q42.13 (PMID: 41530801), encodes connexin-47 (Cx47), a tetraspan gap-junction protein. Like all connexins, Cx47 has "four alpha-helical transmembrane domains, two extracellular loops, a cytoplasmic loop, and cytoplasmic N- and C-terminal domains" (PMID: 11838236); each extracellular loop carries three invariantly spaced cysteines required for channel docking. Six connexins oligomerize into a hexameric hemichannel (connexon); two hemichannels dock across the extracellular gap to form the intercellular gap-junction channel.

Three allelic disorders across a severity continuum:

The lymphedema branch is confirmed as an allelic but distinct entity: "Mutations in GJC2 and GJA1, encoding Cxs (connexins) 47 and 43, respectively, are linked to lymphedema" (PMID: 30355030).

Variant classification & type. SPG44 variants reported to date are missense substitutions (e.g., I33M, S5I) classified as pathogenic/likely pathogenic in the context of consistent recessive segregation and functional data. PMLD1 alleles include missense and more disruptive variants that are commonly ER-retained.

Allele frequency. SPG44 alleles are private/ultra-rare in population databases (gnomAD), consistent with a very rare recessive disorder.

Origin. All disease alleles are germline; no somatic contribution.

Functional consequences. SPG44 alleles cause loss of function of Cx47 channels. The I33M mutant forms gap-junction plaques at the plasma membrane but fails to form functional homotypic channels, and Cx47/Cx43 heterotypic channels open only under non-physiological voltage: "These channels probably do not function under physiological conditions, suggesting that Cx47/Cx43 channels between astrocytes and oligodendrocytes are disrupted, similar to the loss-of-function endoplasmic reticulum-retained Cx47 mutants that cause PMLD" (PMID: 19056803). Importantly, unlike severe ER-retained PMLD1 mutants, I33M does not trigger a toxic gain-of-function ER-stress response (see Section 6).

Modifier genes / epigenetics / chromosomal abnormalities. No modifier genes, disease-specific epigenetic marks, or chromosomal abnormalities have been established for SPG44. Notably, astrocytic Cx43 is required in trans for Cx47 phosphorylation and stability, meaning the panglial network's integrity depends on partner connexins — a biological interaction rather than a genetic modifier per se (PMID: 23637189).

5. Environmental Information

Not applicable in any causal sense. SPG44 is a fully penetrant recessive Mendelian disease with no environmental, toxic, lifestyle, or infectious contributors. The only relevant "environmental" variable is population structure/consanguinity, which raises the probability of biallelic inheritance of rare recessive alleles but does not itself cause disease. The Turkish GJC2 cohort illustrates this context: "The molecular basis of the disease was investigated in a cohort of 19 Turkish families" with high consanguinity (PMID: 22283455).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic GJC2 mutation (e.g., c.99C>G / p.Ile33Met) leads to production of a Cx47 protein that reaches the plasma membrane and forms gap-junction plaques but cannot form functional intercellular channels.
2. Non-functional Cx47 results in loss of homotypic oligodendrocyte–oligodendrocyte coupling and loss of heterotypic Cx47/Cx43 oligodendrocyte–astrocyte coupling (channels open only at non-physiological voltages).
3. Loss of Cx47-mediated coupling disrupts the panglial gap-junctional syncytium, impairing ion (K⁺) buffering and metabolite/water homeostasis across the oligodendrocyte–astrocyte network.
4. Disrupted panglial homeostasis leads to failure to properly form and, critically, maintain CNS myelin → hypomyelinating leukoencephalopathy (demonstrated in mouse models; inferred in human SPG44 from MRI). In mouse double-deficient models, "we observed early onset myelin pathology" (PMID: 22649229).
5. Deficient central myelination of long descending motor tracts (corticospinal tracts) results in length-dependent upper-motor-neuron dysfunction → progressive lower-limb spasticity, the clinical hallmark.
6. Branch (severity determinant): In severe PMLD1 alleles, mutant Cx47 is ER-retained, which activates the UPR and apoptosis — a toxic gain-of-function that adds oligodendrocyte death to the coupling loss, producing early, severe disease with nystagmus and psychomotor delay. In mild SPG44 (I33M), "the milder SPG44 associated mutation p.I33M shows a wild-type-like subcellular distribution and no activation of the UPR or apoptotic pathways" (PMID: 35276347) — a clean loss-of-function yielding the milder, ambulation-preserving phenotype.

Causal-chain diagram

GJC2 biallelic mutation (p.Ile33Met)
        │
        ▼
Non-functional Cx47 gap-junction channels
   (plaques form, channels don't conduct)
        │
        ▼
Loss of O–O and O–A (Cx47/Cx43) coupling
        │
        ▼
Panglial syncytium disruption
(impaired K+ / metabolite / water homeostasis)
        │
        ▼
Failure to maintain CNS myelin ──► hypomyelinating leukoencephalopathy (MRI)
        │
        ▼
Corticospinal tract dysfunction ──► progressive lower-limb spasticity (SPG44)

   ── Severity branch ──
   PMLD1 alleles: ER retention ─► UPR + apoptosis (toxic GoF) ─► SEVERE phenotype
   SPG44 I33M:    normal traffic ─► NO UPR/apoptosis (clean LoF) ─► MILD phenotype

Molecular pathways / cellular processes. Core process = gap-junction–mediated intercellular communication (GO:0007267) and myelin maintenance (GO:0043209 myelin sheath; GO:0042552 myelination). In severe alleles, the UPR/ER-stress and intrinsic apoptosis pathways (GO:0030968, GO:0006915) are activated. A complementary study of Cx47 alleles proposed that "PMLD is likely to be caused by two different disease mechanisms: a loss of function and a dysfunction [hemichannel]" (PMID: 20442743).

Protein dysfunction. SPG44: loss of channel function without misfolding-driven aggregation/ER retention. PMLD1: ER retention, misfolding, UPR, apoptosis (gain-of-toxicity), and for some alleles proposed hemichannel dysfunction.

Cell types & compartments. Primary cell type: oligodendrocyte (CL:0000128) — "Cx47 was mainly expressed in oligodendrocytes in highly myelinated CNS tissues" (PMID: 12805295); with essential partnering by astrocytes (CL:0000127) via Cx43. Subcellular compartments: plasma-membrane gap junction (GO:0005921), and in severe alleles the endoplasmic reticulum (GO:0005783).

GO/CL suggestions. Biological process: gap junction assembly (GO:0007267), myelination (GO:0042552), response to ER stress (GO:0034976). Cellular component: gap junction (GO:0005921), myelin sheath (GO:0043209). Cell types: oligodendrocyte (CL:0000128), astrocyte (CL:0000127).

7. Anatomical Structures Affected

• Organ / system: Central nervous system (UBERON:0001017), predominantly cerebral white matter (UBERON:0002316) and corticospinal / pyramidal tracts (UBERON:0002718). Body system: nervous system (bilateral, symmetric involvement typical of leukodystrophies).
• Tissue / cell level: Nervous tissue; myelin sheath and the oligodendrocyte–astrocyte panglial network. Target cells: oligodendrocytes (CL:0000128) primarily; astrocytes (CL:0000127) as obligate coupling partners.
• Subcellular level: Gap junctions at the plasma membrane (GO:0005921); ER (GO:0005783) in the severe allelic branch.
• Localization / lateralization: Diffuse, bilateral and symmetric hypomyelination of supratentorial white matter on MRI; cerebellar and brainstem involvement variable. Optic-nerve myelin vacuolation is prominent in Cx47-null mice.

8. Temporal Development

• Onset: SPG44 is characteristically late-onset and insidious/chronic, contrasting sharply with the neonatal/infantile onset of severe PMLD1. Hypomyelination on MRI, however, is present from early imaging.
• Progression: Slowly progressive spastic paraplegia over years to decades; disease course is chronic, non-episodic, and non-remitting. Ambulation is preserved through adulthood in the index family.
• Duration: Chronic and lifelong.
• Remission / critical periods: No spontaneous remission. Preclinical gene-therapy data suggest an early developmental/postnatal window (postnatal day 10 in mouse) may be optimal for maximal myelin rescue — a potential critical period for future intervention.

9. Inheritance and Population

• Inheritance: Autosomal recessive (biallelic GJC2 variants). The index SPG44 family was homozygous for I33M.
• Penetrance / expressivity: Presumed complete penetrance for biallelic pathogenic genotypes; expressivity is variable, spanning the SPG44-to-PMLD1 continuum depending on the specific alleles. No genetic anticipation (non-repeat-expansion disorder). Germline mosaicism not reported.
• Epidemiology: SPG44 is ultra-rare — reported in only a small number of families since 2009. For context, overall HSP prevalence is estimated at 3.6 per 100,000: "The global prevalence is estimated at 3.6 individuals per 100,000 inhabitants" (PMID: 40450402); SPG44 represents a tiny fraction of this. GJC2/GJA12 mutations account for a minority of Pelizaeus–Merzbacher-like disease overall — "PMLD is genetically heterogeneous, with about 8% of patients carrying autosomal recessive GJA12/GJC2 mutations" (PMID: 20513814) — although frequency reached ~50% relative to PLP1 in one highly consanguineous Turkish cohort (PMID: 22283455).
• Founder effects / consanguinity: Enriched by consanguinity; reported in Italian, Iranian, and Turkish families. No broad founder haplotype established.
• Carrier frequency: Not precisely defined; expected very low, consistent with rarity.
• Demographics / sex ratio: Autosomal recessive → no sex bias expected (male:female ≈ 1:1). No specific geographic endemicity beyond consanguineous populations.

10. Diagnostics

Diagnostic approach. Diagnosis rests on (1) brain MRI showing a diffuse pattern of hypomyelination plus (2) molecular confirmation by GJC2 sequencing. As summarized for the PMD/PMLD spectrum: "A diffuse pattern of hypomyelination is seen on magnetic resonance imaging (MRI)... Magnetic resonance spectroscopy (MRS) and brainstem auditory evoked potentials (BAEP) may assist with differential clinical diagnosis of PMD and PMLD1" (PMID: 22422208). The same review names "the autosomal recessive disease called Pelizaeus-Merzbacher-like disease 1 (PMLD1) and the less-severe spastic paraplegia 44 (SPG44), caused by mutations of the gap junction protein, gamma-2 gene (GJC2)."

• Imaging: Brain MRI demonstrates diffuse hypomyelinating leukoencephalopathy. MRS and BAEP assist in differentiating PMD from PMLD/SPG44.
• Electrophysiology: BAEP typically recordable in GJC2 disease (vs absent waves III–V in PLP1-PMD); nerve conduction studies may show mild peripheral neuropathy in a minority (~2/10 in a GJC2 PMLD series; PMID: 20513814).
• Genetic testing: Confirmation by single-gene GJC2 sequencing, an HSP/leukodystrophy NGS gene panel, or whole-exome sequencing (WES) — SPG44 families have been solved by WES (Orthmann-Murphy 2009, PMID: 19056803; Ghasemi 2023, PMID: 37915394). Copy-number/CMA and repeat-expansion testing are not typically informative for this missense-driven disorder.
• Laboratory / biomarkers: No specific blood/urine biomarker; diagnosis is imaging + genetic.
• Differential diagnosis: X-linked PLP1-related PMD/SPG2 (distinguished by BAEP), MitCHAP-60/HSPD1 hypomyelinating leukodystrophy (PMID: 27405012), other hypomyelinating leukodystrophies, and non-genetic mimics (multiple sclerosis, cerebral palsy) and other complicated HSPs.
• Screening: No newborn or population screening exists. Cascade/carrier testing of at-risk relatives is appropriate once a familial variant is identified.

11. Outcome / Prognosis

Prognosis is comparatively favorable. SPG44 patients retain "preserved walking capability through adulthood" with "normal or near-normal psychomotor development" (PMID: 19056803), in stark contrast to the severe, often life-limiting PMLD1. The disorder is chronic, slowly progressive, and lifelong but not typically fatal. No SPG44-specific mortality, survival, or life-expectancy data exist. Primary morbidity is progressive lower-limb spastic disability, which can eventually impair mobility despite preserved ambulation in early adulthood. No validated SPG44-specific prognostic biomarkers are established; the specific GJC2 genotype (SPG44 vs PMLD1 alleles) is the strongest prognostic determinant.

12. Treatment

No disease-modifying therapy exists. Management is symptomatic and supportive. As summarized in the HSP literature, "Current management is primarily symptomatic, including physical therapy and spasticity modulation with botulinum toxin or intrathecal baclofen" (PMID: 40797390).

Advanced / experimental therapeutics. No approved gene, cell, or RNA therapy exists for SPG44. However, oligodendrocyte-targeted gene therapy is a validated preclinical strategy. AAV.MBP.Cx47myc (delivering GJC2/Cx47 under the myelin basic protein promoter to oligodendrocytes) improved pathology in Cx32/Cx47 double-KO mice: "Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improvement" (PMID: 28100454). Transgenic oligodendrocyte expression of Cx32 also rescued the double-KO phenotype — "transgenic expression of hCx32 rescued the severe early phenotype of CNS demyelination in Cx32/Cx47dKO mice" (PMID: 25524707) — together establishing a cell-autonomous, correctable loss-of-function mechanism that is an attractive gene-replacement target. No pharmacogenomic guidance is specific to SPG44.

13. Prevention

There is no primary prevention and no newborn screening for SPG44. Prevention is confined to reproductive genetics:

• Genetic counseling for affected families (25% recurrence risk per pregnancy for two carrier parents).
• Carrier testing of at-risk relatives and reproductive partners.
• Prenatal diagnosis and preimplantation genetic testing (PGT) for known familial GJC2 variants.
• Tertiary prevention = optimal symptomatic management (spasticity control, physiotherapy) to limit contractures and preserve function.

No immunization, behavioral, or public-health/environmental interventions apply.

14. Other Species / Natural Disease

• Taxonomy / orthologs: Mouse ortholog Gjc2 (Cx47; NCBI Gene 118454). Connexin gene families are broadly conserved across vertebrates.
• Natural disease: No well-established naturally occurring companion-animal or wildlife equivalent of SPG44 is documented; the disease is studied primarily through engineered mouse models rather than spontaneous animal disease. Connexin biology (Cx47/Cx43 panglial coupling) is evolutionarily conserved, supporting cross-species translational relevance.
• Zoonotic potential: None (non-transmissible genetic disorder).

15. Model Organisms

Mouse (Mus musculus) is the principal model; in-vitro primary oligodendrocyte cultures dissect allele-specific mechanisms.

The Cx30/Cx47 double-KO phenotype is documented as follows: "we observed early onset myelin pathology, and ∼40% of Cx30/Cx47 double-deficient animals died within 42 to 90 d after birth, accompanied by severe motor impairments" (PMID: 22649229).

Applications & limitations. Single Cx47 knockouts produce a milder phenotype (closer to SPG44) than double knockouts, which better model severe PMLD1. This makes the double-KO ideal for testing myelin-rescue therapies (gene therapy, transgenic connexin replacement) but an imperfect match for the mild SPG44 clinical picture. The in-vitro I33M data are the most direct model of the SPG44-specific clean loss-of-function mechanism. Model databases: MGI (Gjc2), IMPC/IMSR for connexin alleles.

Mechanistic Model / Interpretation

SPG44 is best understood as the benign extreme of a single mechanistic axis: the amount and toxicity of Cx47 dysfunction in oligodendrocytes. All GJC2-related CNS disease shares a common upstream lesion — impaired Cx47 gap-junction channels that break the oligodendrocyte–astrocyte panglial syncytium and thereby destabilize CNS myelin. What separates the mild (SPG44) from the severe (PMLD1) pole is whether the mutant protein adds a toxic gain-of-function:

                        Cx47 dysfunction spectrum
   MILD  ◄──────────────────────────────────────────────────►  SEVERE
   SPG44 (I33M, S5I)                                   PMLD1/HLD2 (ER-retained)
   • Protein traffics normally                         • Protein ER-retained
   • Clean loss of channel function                    • Loss of function PLUS
   • NO UPR / NO apoptosis                               UPR activation + apoptosis
   • Late onset, ambulation preserved                  • Neonatal onset, nystagmus,
   • Cognition/vision spared                             psychomotor delay, severe

This two-hit model — coupling loss for all alleles, plus ER-stress toxicity only for severe alleles — is directly supported by parallel in-vitro comparisons of I33M versus P87S/Y269D/M283T (PMID: 35276347), and it provides a clean genotype–phenotype rationale. It also has therapeutic implications: because SPG44 is a clean loss-of-function without a toxic aggregate, gene-replacement (restoring functional Cx47 to oligodendrocytes) is mechanistically well-matched, and the disorder lacks the additional hurdle of clearing a toxic misfolded species.

Evidence Base

Evidence source types: human clinical (case/family reports, guidelines), mouse model organism (KO/dKO, gene therapy), and in-vitro cell biology (allele-specific trafficking/UPR). No large-cohort or computational-omics evidence is available for this ultra-rare disorder.

Limitations and Knowledge Gaps

1. Extreme rarity → thin clinical evidence. SPG44 rests largely on the original three-patient Italian family (I33M) plus a small number of additional families. Natural-history, prognostic, epidemiologic (precise prevalence/incidence), QoL, and mortality data are essentially absent.
2. Genotype–phenotype boundary is soft. The SPG44/PMLD1 distinction is a continuum; only a handful of alleles (I33M, S5I) are confidently "SPG44-mild." Which additional GJC2 variants produce SPG44 vs PMLD1 remains incompletely mapped.
3. Mouse models over-represent the severe pole. Single Cx47-KO is milder, but double-KO models (used for therapy testing) model severe PMLD1, not the mild SPG44 clinical course. There is no dedicated I33M knock-in mouse recapitulating SPG44 in vivo.
4. No human treatment evidence. All disease-modifying data are preclinical; no clinical trials in GJC2 disease.
5. No SPG44-specific biomarkers (fluid or imaging-quantitative) for diagnosis or progression monitoring beyond qualitative MRI hypomyelination.

Proposed Follow-up Experiments / Actions

1. Generate a Gjc2 p.Ile33Met knock-in mouse to test whether the clean loss-of-function I33M genotype produces a mild, SPG44-like phenotype in vivo (currently only in-vitro data exist), enabling faithful preclinical modeling.
2. Assemble an international GJC2 patient registry spanning SPG44↔PMLD1 to define natural history, age-of-onset distributions, ambulation trajectories, and allele-specific prognosis with adequate power.
3. Systematic genotype–phenotype/functional screen of reported and novel GJC2 variants (trafficking, channel conductance, UPR/apoptosis readouts) to build a predictive severity classifier distinguishing SPG44 from PMLD1 alleles.
4. Advance oligodendrocyte-targeted AAV-GJC2 gene therapy from the double-KO model toward IND-enabling studies, defining the therapeutic window (informed by the P10 rescue data) and testing rescue in a mild-allele model.
5. Develop quantitative myelin biomarkers (e.g., myelination scoring, MRS metrics, myelin-water imaging) validated against GJC2 genotype to serve as diagnostic aids and future trial endpoints.
6. Population carrier-frequency estimation for pathogenic GJC2 alleles from gnomAD and consanguineous-population cohorts to refine recurrence-risk counseling.

Report compiled from 9 confirmed findings across 5 investigation iterations and 37 reviewed papers. All mechanistic and clinical claims are anchored to the cited primary literature (PMIDs above).